It has been shown that methylation of CpG dinucleotides located in the promoter region of TP53 is associated with low expression levels of this gene. We have analysed the methylation status of one CpG dinucleotide and of three CCWGG motifs, also located in the promoter region of the gene, in bone marrow samples obtained from patients with acute lymphoblastic leukemia (ALL). Eight out of 25 samples analysed showed methylation of either the CpG dinucleotide, the CCWGG motifs or both. Relative to nonmethylated leukemia samples, TP53 expression levels were decreased in all methylated samples in which TP53 expression could be measured. Methylation of CpG and CCWGG motifs in the promoter of TP53 could represent a novel mechanism leading to functional impairment of this tumor suppressor gene in ALL.
Promoter methylation is a well-recognized mechanism for the transcriptional silencing of various tumor suppressor genes (Herman et al., 1996; Schutte et al., 1997) . Such methylation is typically restricted to cytosines in CpG dinucleotides located within CpG islands. However, a recent study has shown that the internal cytosine in the motif CCWGG is also a substrate for methylation in the B29 gene promoter in mature B-cell lymphoma cell lines (Malone et al., 2001) .
TP53 is a tumor suppressor gene involved in the control of the cell cycle and apoptosis, mutated in a significant number of hematological malignancies (Fenaux and Preudhomme, 1997) . It is one of the few tumor suppressor genes not containing a canonical CpG island associated to its promoter region (Bienz-Tadmor et al., 1985) , but the proximal promoter (including noncoding exon 1) contains several CpG dinucleotides and CCWGG motifs (Bienz-Tadmor et al., 1985; Tuck and Crawford, 1989) . In vitro studies have shown that methylation of CpG dinucleotides in the promoter region of TP53 results in decreased expression levels (Mass and Wang, 1997; Schroeder and Mass, 1997; Davis et al., 2000; Pogribny et al., 2000) . However, there is little information about the frequency of this event in primary tumors (Kang et al., 2001; Pogribny and James, 2002) , and the possible methylation of TP53 has not been addressed in hematological malignancies. Likewise, methylation of CCWGG motifs has never been studied in this gene.
In this work, we have analysed the methylation pattern of one CpG dinucleotide and three CCWGG motifs in the promoter region of TP53 (Figure 1a ) in 25 bone marrow samples from patients with acute lymphoblastic leukemia (ALL), 18 with a B phenotype and seven with a T phenotype. All samples were obtained at the moment of diagnosis. As controls, we used samples from three healthy volunteers.
We have detected methylation in the promoter region of TP53 in eight out of 25 patients with ALL. Two samples showed methylation in all sites analysed (one CpG dinucleotide and three CCWGG motifs), five samples were only methylated in the CCWGG motifs, and one sample was methylated in the CpG dinucleotide only (Figure 1b) .
Analysis of TP53 mRNA expression by semiquantitative RT-PCR could be performed in five of the eight methylated samples (two samples showing methylation in all cytosines studies, three samples showing methylation of the CCWGG motifs only). TP53 mRNA levels in methylated samples were between 0 and 63% of controls (two nonmethylated ALL samples), as shown in Figure 2 .
It is unclear whether the degree of methylation detected in our samples can account for reductions in TP53 expression of the magnitude observed. Although TP53 inactivation is generally caused through deletion and mutation, several studies have shown that in vitro methylation of the promoter results in decreased transcriptional activity both in human and rat (Schroeder and Davis et al., 2000; Pogribny et al., 2000) . Likewise, CpG methylation is responsible for the drop in TP53 expression observed in human primary hepatocellular carcinoma (Pogribny and James, 2002) .
In this regard, it must be emphasized that all patient samples were also subjected to TP53 mutational screening using a sensitive denaturing gradient gel electrophoresis procedure (Agirre et al., 2002) and that TP53 gene copy number was assessed by FISH (not shown). It is interesting to note that those samples with the lowest levels of TP53 expression (0 and 16% relative to nonmethylated ALL samples) had a duplication of one allele in addition to promoter methylation.
Except for one sample in which no TP53 expression could be detected, the rest of the samples analysed showed some degree of residual expression. This contradicts the classical view of tumor suppressor genes, which would require the complete loss of function of the gene in order to promote tumor progression, but one must take into account the normal, nonleukemic cells present in the bone marrow of these patients. Furthermore, it has been shown that decreased TP53 expression can account for the promotion of tumor development in TP53 +/-heterozygous mice (Venkatachalam et al., 1998) . It is thus possible that methylation of the TP53 promoter could represent a new form of gene inactivation, contributing to tumor initiation and/or progression DNA was extracted from bone marrow using QIAmp DNA Mini Kit (Qiagen, Hilden, Germany). Genomic DNA was digested with methylation-sensitive restriction enzymes Hpa II (for CpG dinucleotides) and EcoR II (for CCWGG motifs), and the digested DNA was amplified by PCR. For each sample, 0.5 mg of DNA was digested overnight separately with each enzyme, together with a negative control to which no enzyme had been added. After digestion, a duplex PCR was performed to coamplify the promoter region of TP53 and exon 6 of the same gene. We chose exon 6 because it does not contain any restriction sites for these enzymes, and can be used as internal control in the reaction. Hot-start PCR amplification was performed under standard conditions using AmpliTaq s Gold polymerase (Applied Biosystems, Foster City, CA, USA), 28 cycles at an annealing temperature of 601C and 0.1 mm of each primer (
E6R ¼ 5 0 -AGACCCCAGTTGCAAACCAG). In these assays, unmethylated sites are digested and cannot be amplified, whereas the presence of a methylated cytosine prevents digestion and results in successful amplification. As positive control, DNA methylated in vitro with Sss I methylase was used. Digestion controls were performed with Msp I and BstN I, which recognize the same sites as Hpa II and EcoR II, respectively, but are methylation-insensitive. For each sample, 'À' shows the PCR amplification with no restriction enzyme added to the digestion reaction and '+' shows the PCR amplification after digestion with the enzyme indicated. The top gel corresponds to Hpa II digestion and the bottom gel to EcoR II digestion. In both gels, the lower band corrresponds to TP53 exon 6 and the upper band corresponds to the promoter region that encompasses the restriction sites Figure 2 Methylation status and expression levels of TP53. Total RNA was extracted using RNeasy Mini Kit (Qiagen, Hilden, Germany), and 1 mg was used for cDNA synthesis using SuperScriptt II RNase H -RT (Invitrogen Life Technologies, Paisley, UK) with random hexamers. Semiquantitative analysis of TP53 expression was performed by RT-PCR using primers RT3 (5 0 -ACTGGCGCTAAAAGTTTTGA) and RT4 (5 0 -ATTCTGG GAGCTTCATCTGG) for TP53 (36 cycles, 561C) and primers BMGF (5 0 -GAATTCACTCAATCCAAATG) and BMGR (5 0 -ATTTCCTGAATTGCTATGTG) for b-2-microglobulin (b2MG) (used as an internal control, 32 cycles, 561C). All reactions were kept in the linear phase of amplification, and the ratio of TP53 to b2MG was determined densitometrically. Results are expressed as the ratio of TP53 to b2MG expression. The percentages in brackets indicate expression levels relative to C1 and C2 (nonmethylated ALL samples used as controls). 
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The average of these samples (0.51) was taken as 100% expression in ALL patients. Recently, it has been found that methylation of the p21 promoter is a frequent event in ALL (Roman-Gomez et al., 2002) , suggesting that methylation could be a common mechanism for the inactivation of components of the p53 pathway.
In summary, we have found a high proportion of ALL samples (8/25, 32%) showing TP53 promoter methylation at diagnosis. Furthermore, we show for the first time that CCWGG motifs within this promoter are also methylated in this tumor type, and that such methylation is found either as isolated events or in conjunction with CpG dinucleotide methylation in the same region, demonstrating decreased TP53 gene expression in all the methylated samples that were analysed. These findings support the notion that methylation could represent a novel mechanism for TP53 inactivation in this type of malignancies.
